Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jenifer R Prosperi

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Current Drug Targets|November 9, 2013
Exploiting APC function as a novel cancer therapyAlyssa C Lesko, Kathleen H Goss, Jenifer R Prosperi
Neoplasia (New York, N.Y.)|November 24, 2019
APC loss affects DNA damage repair causing doxorubicin resistance in breast cancer cellsCasey D Stefanski, Kaitlyn Keffler, Stephanie McClintock, et al.
Plos One|January 5, 2012
Apc mutation enhances PyMT-induced mammary tumorigenesisJenifer R Prosperi, Andrey I Khramtsov, Galina F Khramtsova, et al.
BMC Cancer|June 8, 2015
APC selectively mediates response to chemotherapeutic agents in breast cancerMonica K VanKlompenberg, Claire O Bedalov, Katia Fernandez Soto, et al.
BMC Cancer|November 30, 2016
Erratum to: APC selectively mediates response to chemotherapeutic agents in breast cancerMonica K VanKlompenberg, Claire O Bedalov, Katia Fernandez Soto, et al.
Cancers|November 13, 2020
Mechanisms of Taxane ResistanceSara M Maloney, Camden A Hoover, Lorena V Morejon-Lasso, et al.
Plos One|February 7, 2015
β-Catenin is required for the tumorigenic behavior of triple-negative breast cancer cellsJinhua Xu, Jenifer R Prosperi, Noura Choudhury, et al.
Frontiers in Immunology|June 30, 2025
Editorial: Clinical implementation of precision oncology data to direct individualized and immunotherapy-based treatment strategiesNicholas A Young, Jenifer R Prosperi, Aharon G Freud, et al.
Prostaglandins & Other Lipid Mediators|August 5, 2004
Invasive and angiogenic phenotype of MCF-7 human breast tumor cells expressing human cyclooxygenase-2Jenifer R Prosperi, Susan R Mallery, Kristina A Kigerl, et al.
Oncotarget|December 22, 2017
APC loss in breast cancer leads to doxorubicin resistance via STAT3 activationMonica K VanKlompenberg, Emily Leyden, Anne H Arnason, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Current Drug Targets|November 9, 2013
Exploiting APC function as a novel cancer therapyAlyssa C Lesko, Kathleen H Goss, Jenifer R Prosperi
Neoplasia (New York, N.Y.)|November 24, 2019
APC loss affects DNA damage repair causing doxorubicin resistance in breast cancer cellsCasey D Stefanski, Kaitlyn Keffler, Stephanie McClintock, et al.
Plos One|January 5, 2012
Apc mutation enhances PyMT-induced mammary tumorigenesisJenifer R Prosperi, Andrey I Khramtsov, Galina F Khramtsova, et al.
BMC Cancer|June 8, 2015
APC selectively mediates response to chemotherapeutic agents in breast cancerMonica K VanKlompenberg, Claire O Bedalov, Katia Fernandez Soto, et al.
BMC Cancer|November 30, 2016
Erratum to: APC selectively mediates response to chemotherapeutic agents in breast cancerMonica K VanKlompenberg, Claire O Bedalov, Katia Fernandez Soto, et al.
Cancers|November 13, 2020
Mechanisms of Taxane ResistanceSara M Maloney, Camden A Hoover, Lorena V Morejon-Lasso, et al.
Plos One|February 7, 2015
β-Catenin is required for the tumorigenic behavior of triple-negative breast cancer cellsJinhua Xu, Jenifer R Prosperi, Noura Choudhury, et al.
Frontiers in Immunology|June 30, 2025
Editorial: Clinical implementation of precision oncology data to direct individualized and immunotherapy-based treatment strategiesNicholas A Young, Jenifer R Prosperi, Aharon G Freud, et al.
Prostaglandins & Other Lipid Mediators|August 5, 2004
Invasive and angiogenic phenotype of MCF-7 human breast tumor cells expressing human cyclooxygenase-2Jenifer R Prosperi, Susan R Mallery, Kristina A Kigerl, et al.
Oncotarget|December 22, 2017
APC loss in breast cancer leads to doxorubicin resistance via STAT3 activationMonica K VanKlompenberg, Emily Leyden, Anne H Arnason, et al.
Pageof 3